Trevi Therapeutics earnings were -$47.3M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest TRVI earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$10.3M, down 9.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TRVI reported annual earnings of -$47.9M, with 64.8% growth.
What were Trevi Therapeutics's earnings last quarter?
On TRVI's earnings call on Invalid Date, Trevi Therapeutics (NASDAQ: TRVI) reported Q1 2025 earnings per share (EPS) of -$0.09, up 18.18% year over year. Total TRVI earnings for the quarter were -$10.34 million. In the same quarter last year, Trevi Therapeutics's earnings per share (EPS) was -$0.11.
As of the last Trevi Therapeutics earnings report, Trevi Therapeutics is currently losing money. Trevi Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$47.35 million, a 41.06% increase year over year.
What was TRVI's earnings growth in the past year?
As of Trevi Therapeutics's earnings date in Invalid Date, Trevi Therapeutics's earnings has grown year over year. TRVI earnings in the past year totalled -$47.35 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.